Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
about
Brain tumorsPseudoprogression in high-grade glioma.Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patientsComparison of magnetic resonance spectroscopy and positron emission tomography in detection of tumor recurrence in posttreatment of glioma: A diagnostic meta-analysis.Post-treatment imaging changes in primary brain tumors.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Imaging in neurooncology[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma.Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities.Diagnostics of cerebral gliomas with radiolabeled amino acids.PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed.Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET.Diagnosis of Brain Tumors Using Amino Acid Transport PET Imaging with 18F-fluciclovine: A Comparative Study with L-methyl-11C-methionine PET Imaging.Imaging changes following stereotactic radiosurgery for metastatic intracranial tumors: differentiating pseudoprogression from tumor progression and its effect on clinical practice.Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.Molecular imaging of gliomas with PET: opportunities and limitations.Radiation necrosis following treatment of high grade glioma--a review of the literature and current understanding.Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression.A preliminary quantitative proteomic analysis of glioblastoma pseudoprogressionFDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosisThe use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.Kinetic Modeling and Graphical Analysis of 18F-Fluoromethylcholine (FCho), 18F-Fluoroethyltyrosine (FET) and 18F-Fluorodeoxyglucose (FDG) PET for the Fiscrimination between High-Grade Glioma and Radiation Necrosis in Rats.Consequences of additional use of contrast-enhanced (18)F-FDG PET/CT in target volume delineation and dose distribution for pancreatic cancer.Positron emission tomography: clinical applications in oncology. Part 2.NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studiesMagnetic resonance spectroscopic study of radiogenic changes after radiosurgery of cerebral arteriovenous malformations with implications for the differential diagnosis of radionecrosis.Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinomaDiagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue NecrosisPerfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas.Methodology for quantitative rapid multi-tracer PET tumor characterizationsA prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis†.An automated voxel-based method for calculating the reference value for a brain tumour metabolic index using 18F-FDG-PET and 11C-methionine PET.Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategiesResponse Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats.Clinical Utility of Positron Emission Tomography in Patients with Malignant Glioma.A comparison study of (11)C-methionine and (18)F-fluorodeoxyglucose positron emission tomography-computed tomography scans in evaluation of patients with recurrent brain tumors.Paediatric nuclear medicine imaging.
P2860
Q24605136-85AA3507-33B3-4C1E-8EA3-733EFF11B8E6Q30578798-59240189-BEC5-4B7F-B5D8-09D4273487AFQ30692995-31D5635F-728B-43CB-AAB1-302553C24610Q30811922-D4AF0F21-01A5-4BCA-8DB9-3EDB08CD0E8FQ30835236-4440AA9C-5B15-4B40-9942-1818767BE6D1Q30907831-C7F9813B-6AC0-421A-9071-D1B25280A6FCQ30989939-19BC7EB1-E7EE-45CC-9CC1-47D7727FA2E3Q33395877-B188C661-F868-4A6E-BE23-D2FCB38E7955Q33432870-6DC1FB54-FEC4-4520-AA02-17C1F5E8A55BQ33487194-741051B1-7ACD-4058-A06D-43694E8B1037Q33578187-4D827B89-B1A7-4BA3-9FF0-D5D196185147Q33746805-80856B1A-7A17-48E4-B09A-E6BF3E968B75Q33830251-81A1E722-6059-4F93-818C-D8153B205C1DQ33862844-89476E6B-DB58-4C57-9562-9CA33A4D1C7DQ33894461-07BBD626-7548-418B-BC8F-25B12F43C58EQ33961188-A8A67FCF-12EE-43AD-AD67-3495197D0DDAQ34087196-3527BB75-149B-43D1-837F-109634CD4D51Q34193723-D5823B28-71E1-4131-BE25-AD775A180DDDQ35103504-F8B13ECE-15D5-4502-90CF-F206B1779FF1Q35368468-F1B4E381-D2C5-4647-86D8-43129880029EQ35914501-EBF8221B-DE8A-437A-A08D-5939D08201EEQ35943921-FA551B72-DFB3-4647-9765-97F91525421DQ36107374-86B05731-89F9-42C4-93F0-150929AF632FQ36112565-8C1BC7E0-5E6B-4C55-85C5-1226B54211DBQ36235666-5C1B464E-C620-463C-A507-CBEEED8F24ABQ36448703-00D387D6-FD15-425B-A295-BF547301139DQ36539340-CCE08C77-3F4A-4B50-B4A4-D1D3477ABFB6Q36753743-C9B4E9B3-9E51-4C9A-A613-0E8D2F0532BEQ36924872-19AF3AE8-9050-4713-AC34-A1614B1176DBQ37016981-07E65DCC-D5C4-4D91-B156-09FFB8FD9952Q37092483-2DC74F43-7616-4760-B72A-D38721A73422Q37342653-2E663E95-29C3-47FE-879A-B5F9C9E0937BQ37400326-EE5E8375-0E68-42E8-9E51-2CFC8E66C45BQ37703206-6934833D-6675-4BDF-98D2-673635353DD9Q38074638-D0D21187-57EC-4365-ABE9-4560198C4781Q38815396-DE3402E9-1612-432F-A730-8AC0EC93141AQ38902139-9D047963-F364-4448-A547-C3CA44AD6B6EQ39274022-07D4E8CF-AF2A-4AC4-B04A-9DD0CC285FDAQ39724277-A49F1AE0-CBAB-45A2-BFAB-35E7686AE200Q40045765-474ECE4B-163C-4B7A-AD55-1C05DB4C37CE
P2860
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Direct comparison of 18F-FDG a ...... iability and prognostic value.
@en
Direct comparison of 18F-FDG a ...... iability and prognostic value.
@nl
type
label
Direct comparison of 18F-FDG a ...... iability and prognostic value.
@en
Direct comparison of 18F-FDG a ...... iability and prognostic value.
@nl
prefLabel
Direct comparison of 18F-FDG a ...... iability and prognostic value.
@en
Direct comparison of 18F-FDG a ...... iability and prognostic value.
@nl
P2093
P2860
P1476
Direct comparison of 18F-FDG a ...... iability and prognostic value.
@en
P2093
Frank Van Calenbergh
Guy Bormans
Johan Menten
Koen Van Laere
Luc Mortelmans
Patrick Flamen
Sarah Ceyssens
Tjibbe de Groot
P2860
P2888
P356
10.1007/S00259-004-1564-3
P577
2004-08-10T00:00:00Z
P6179
1043340294